Analysts Set Enovis Corporation (NYSE:ENOV) PT at $51.17

Shares of Enovis Corporation (NYSE:ENOV) have been given a consensus recommendation of “Moderate Buy” by the seven ratings firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $49.8333.

Several research firms have commented on ENOV. Wells Fargo & Company increased their target price on Enovis from $41.00 to $42.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Enovis in a research report on Wednesday, October 8th. Finally, Canaccord Genuity Group cut their price target on shares of Enovis from $58.00 to $50.00 and set a “buy” rating on the stock in a report on Wednesday.

Enovis Price Performance

Shares of NYSE:ENOV opened at $27.37 on Thursday. The firm has a 50 day simple moving average of $29.84 and a 200 day simple moving average of $30.40. The company has a market cap of $1.57 billion, a price-to-earnings ratio of -1.16 and a beta of 1.52. Enovis has a one year low of $25.47 and a one year high of $49.38. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.22 and a quick ratio of 1.16.

Enovis (NYSE:ENOV) last announced its quarterly earnings results on Monday, January 8th. The company reported $0.59 earnings per share (EPS) for the quarter. Enovis had a negative net margin of 61.22% and a positive return on equity of 7.79%. The company had revenue of $383.81 million during the quarter. Research analysts predict that Enovis will post 2.79 earnings per share for the current fiscal year.

Insider Transactions at Enovis

In related news, insider John Kleckner acquired 2,468 shares of the business’s stock in a transaction that occurred on Tuesday, November 25th. The shares were bought at an average cost of $30.32 per share, with a total value of $74,829.76. Following the completion of the purchase, the insider directly owned 12,302 shares in the company, valued at $372,996.64. The trade was a 25.10% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Daniel A. Pryor sold 999 shares of the company’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $27.20, for a total value of $27,172.80. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 2.70% of the company’s stock.

Institutional Investors Weigh In On Enovis

A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its stake in Enovis by 2.0% during the third quarter. Vanguard Group Inc. now owns 6,524,235 shares of the company’s stock worth $197,945,000 after buying an additional 125,460 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its position in Enovis by 0.7% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 6,207,768 shares of the company’s stock valued at $237,199,000 after buying an additional 44,632 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Enovis by 1.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,971,545 shares of the company’s stock worth $90,156,000 after buying an additional 51,201 shares during the period. Rubric Capital Management LP bought a new position in Enovis in the third quarter worth approximately $83,435,000. Finally, Hood River Capital Management LLC grew its stake in Enovis by 20.3% in the second quarter. Hood River Capital Management LLC now owns 1,735,533 shares of the company’s stock valued at $54,426,000 after acquiring an additional 292,950 shares during the period. 98.45% of the stock is owned by institutional investors.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.